Evotec SE Overview
Pro stress-test →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. The company serves as a strategic partner to pharma and biotech firms, leveraging AI-driven innovation and advanced technologies to accelerate drug development across multiple therapeutic areas. The company works with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders.
Strategic Profile
Pro stress-test →Evotec operates in two segments, Shared R&D and Just – Evotec Biologics. The company is executing a strategic portfolio shift toward higher-margin biologics manufacturing and away from lower-margin discovery services. Evotec signed a sale and license agreement with Sandoz on November 4, 2025, transferring the Just - Evotec Biologics Toulouse site and granting an indefinite license to Evotec's continuous biologics manufacturing platform, with key financial terms including approximately US$350m cash for the site, plus upfront license fees and success-based milestones totalling more than US$300m over coming years.
Competitive Landscape
Pro stress-test →Evotec competes in the crowded CRO/CDMO space against Syneos Health, IQVIA, Parexel (Pamlab), Charles River Laboratories, and WuXi AppTec. The company differentiates through AI-driven platforms, proprietary technology (PanOmics, Molecular Patient Databases, iPSC modeling), and integrated small molecule-to-biologics capabilities. However, discovery services face pricing pressure from larger CROs and emerging competitors.
Industry Context
Evotec SE operates in Pharmaceutical Services / Contract Research Organization (CRO) & Contract Development and Manufacturing Organization (CDMO).
Key facts
Founded: 1993 · Headquarters: Hamburg, Germany · Employees: N/A · Revenue: $797M (2024); €535M (9M 2025) · Market cap: $1.29B